CanSino's COVID-19 vaccine candidate approved for military use in China

Soldiers of China's People's Liberation Army march on Red Square during a military parade which marks the 75th anniversary of the Soviet victory over Nazi Germany in World War Two in Moscow

World Health Organization has said that the coronavirus vaccine created by an Irish scientist and his team, in Oxford, is "the leading candidate"' for a COVID-19 cure. Bharat Biotech chairman Dr Krishna Ella said, "The collaboration with ICMR and NIV was instrumental in the development of this vaccine".

Suchitra Ella, Joint Managing Director, Bharat Biotech, said, "Our ongoing research and expertise in forecasting epidemics enabled us to successfully manufacture a vaccine for the H1N1 pandemic".

COVAXIN, developed by city-based Bharat Biotech in collaboration with ICMR and NIV will undergo Human clinical trials across India in July 2020.

Also in the race are the China National Biotec Group (CNBG), who said on Sunday that early human test results for a coronavirus vaccine candidate suggested it could be safe and effective, the second vaccine candidate from the firm to show encouraging results in a clinical trial. The vaccine was developed using an existing deactivated rabies vaccine as a vehicle for coronavirus proteins, according to a Business Line report.

The agency issued guidance to vaccine developers in conjunction with testimony by FDA Commissioner Stephen Hahn and other health officials before the Senate Health, Education, Labor and Pensions Committee on how schools and businesses can safely reopen amid the pandemic.

Most experts think a coronavirus vaccine is likely to become available by mid-2021, about 12-18 months after the new virus, known officially as Sars-CoV-2, first emerged.

There are more than a dozen Indian initiatives with Corporates and Research Institutes and at various stages of development.

Phases one and two typically indicate whether the vaccine is safe for use without any unwarranted side effects, although all candidates must complete phase three to obtain and license to go on sale.

Ahmedabad-based Cadila Healthcare was the first among Indian players to announce a vaccine candidate - it had also started pre-clinical studies. University of Oxford's vaccine is the furthest in the trial, now in the third phase, while there are various candidates in the second phase.

Doctors are also testing various drugs to find out their effectiveness in fighting against the COVID-19 virus. Tamil Nadu has reported 82275 cases and 1079 deaths.

The Ministry of Home Affairs has released guidelines for Unlock 2.0, which is expected to come into force till 31 July.

Related:

Comments


Other news